The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer
- 27 October 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 20 (15) , 1787-1796
Abstract
Background: Silibinin (SB), the main component of Silymarin (SM), is a natural substance obtained from the seeds of the milk thistle. SM contains up to 70% of SB as two isoforms: A and B. It has an antioxidant and anti-inflammatory effect on hepatocytes and is known to inhibit cell proliferation, induce apoptosis, and curb angiogenesis. SB has demonstrated activity against many cancers, such as skin, liver, lung, bladder, and breast carcinomas. Methods: his review presents current knowledge of the use of SM in breast cancer, this being one of the most common types of cancer in women. It describes selected molecular mechanisms of the action of SM; for example, although SB influences both Estrogen Receptors (ER), α and β, it has opposite effects on the two. Its action on ERα influences the PI3K/AKT/mTOR and RAS/ERK signaling pathways, while by up-regulating ERβ, it increases the numbers of apoptotic cells. In addition, ERα is involved in SB-induced autophagy, while ERβ is not. Interestingly, SB also inhibits metastasis by suppressing TGF-β2 expression, thus suppressing Epithelial to Mesenchymal Transition (EMT). It also influences migration and invasive potential via the Jak2/STAT3 pathway. Results: SB may be a promising enhancement of BC treatment: when combined with chemotherapeutic drugs such as carboplatin, cisplatin, and doxorubicin, the combination exerts a synergistic effect against cancer cells. This may be of value when treating aggressive types of mammary carcinoma. Conclusion: Summarizing, SB inhibits proliferation, induces apoptosis, and restrains metastasis via several mechanisms. It is possible to combine SB with different anticancer drugs, an approach that represents a promising therapeutic strategy for patients suffering from BC.Keywords
This publication has 78 references indexed in Scilit:
- Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cellsVirology Journal, 2013
- Targeting PES1 for restoring the ERα/ERβ ratio in breast cancerJournal of Clinical Investigation, 2012
- Estrogens in the breast tissue: a systematic reviewCancer Causes & Control, 2011
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- Multitargeted therapy of cancer by silymarinCancer Letters, 2008
- TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4Cell, 2008
- Silymarin and epithelial cancer chemoprevention: How close we are to bedside?Toxicology and Applied Pharmacology, 2007
- The role of estrogen in the initiation of breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell lineCancer Science, 2006
- MicroRNA Gene Expression Deregulation in Human Breast CancerCancer Research, 2005